Antithrombotic Therapy in Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Percutaneous coronary intervention (PCI) requires anticoagulation.
• Unfractionated heparin is a common choice, but newer agents are emerging.
• Bleeding risk is a significant concern in PCI, particularly with femoral access and glycoprotein IIb/IIIa inhibition.

Purpose of the Study:

• To review current anticoagulation strategies for PCI.
• To compare the benefits and limitations of various anticoagulant agents.
• To provide guidance on selecting antithrombotic therapy based on ischemic and bleeding risks.

Main Methods:

• Review of existing clinical data and guidelines.
• Comparative analysis of anticoagulant efficacy and safety profiles.
• Focus on agents used in elective, urgent, and emergent PCI settings.

Main Results:

• Accumulating evidence supports newer anticoagulants for reduced bleeding risk.
• Specific scenarios, like femoral access, benefit from alternative agents.
• Balancing antithrombotic efficacy with bleeding complications is key.

Conclusions:

• The choice of anticoagulant in PCI should be individualized.
• Emerging agents offer potential advantages in mitigating bleeding.
• Guidelines emphasize careful risk-benefit assessment for antithrombotic therapy.